Generex Biotechnology Corp. (GNBT)

Antigen Express, Inc. is a wholly owned subsidiary of Generex. Antigen Express is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Our focus is on stimulating critical members of the immune response, known as T helper cells.

Antigen Expres

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for active immunotherapy as well as disease prevention.

In contrast to traditional therapies, the goal of active immunotherapy is to amplify the patients' ability to fight specific disease rather than targeting the diseased tissue or pathogenic agent directly. The novel technologies being developed at Antigen Express allows for robust and antigen-specific stimulation of CD4+ T cells, a cell type critical in the recognition of pathogens and modulation of the immune response.

Antigen Express is developing these technologies for application to the treatment of cancer, infectious diseases, and other serious diseases. Our most advanced vaccine utilizes a self-potentiating peptide as an off-the-shelf product for active immunotherapy of breast and prostate cancer

To find out more on Antigen Express please go to www.antigenexpress.com.

Eric von Hofe, PhD
President

Dr. von Hofe joined Antigen Express in November of 2003. Prior to this time he held two positions at Millennium Pharmaceuticals; first as Program Director for Target Validation, where he presided over technology development efforts for Aventis and Cereon, and second as Director of Programs and Operations, Discovery Research. He received his Ph.D. from the University of Southern California and was a postdoctoral fellow at the University Hospital of Zurich and Harvard. From 1989 to 1992 he was Assistant Professor of Pharmacology at the University of Massachusetts Medical School.

Scientific Advisory Board
 
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
 Dr. Hortobagyi chairs the department of breast medical oncology and directs the Breast Cancer Research Program at the University of Texas M.D. Anderson Cancer Center, where he also serves as professor of medicine and holds the Nellie B. Connally Chair in Breast Cancer.
 Dr. Hortobagyi's research includes combination chemotherapy regimens, presurgical chemotherapy, and targeted therapies for all stages of breast cancer. He has contributed more than 800 articles to scientific journals, authored and co-authored 13 books, and contributed over 130 chapters to textbooks.
For his efforts in breast cancer research, Dr. Hortobagyi has received worldwide honors. In 2001, President Jacques Chirac named him Chevalier of the Order of la Legion d'Honneur de France. In 2003, Dr. Hortobagyi received the Glen Robbins Award in Breast Cancer Research from the New York Cancer Society and the Metropolitan Breast Cancer Group, and the Bristol-Myers Squibb 2003 Horizon Scientific Award. The Mexican Society of Oncology named him the 2005 World Leader in Oncology.
 Dr. Hortobagyi was elected President of the American Society of Clinical Oncology (ASCO) for the 2006-2007 term. He chairs the Breast Committee of the Southwest Oncology Group as well as the Data and Safety Monitoring Committee of the National Surgical Adjuvant Breast and Bowel Project.

Nuhad Ibrahim, MD
The University of Texas MD Anderson Cancer Center
 Dr. Nuhad Ibrahim is a Professor in the Department of Breast Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. He is a leader on the US-Middle East Breast Cancer Awareness & Research Committee, and is on the Steering committee for the Sister Institution relationship between M. D. Anderson Cancer Center and the Faculty of Medicine and Medical Center of the American University of Beirut. He is also a Member of the Institutional Research Grants Program Study Section Review Committee for Clinical Translational and Population-Based Research Projects at MD Anderson. Dr. Ibrahim focuses his research efforts on vaccines in breast cancer, breast geriatric oncology, and treatment of resistant breast cancer.  He has published extensively on his research to improve outcomes for the most difficult to treat breast cancers. Dr. Ibrahim has been recognized as one of America’s Top Doctors annually since 2003.
 Dr. Ibrahim received a dual undergraduate degree in Biology and Chemistry, from American University of Beirut, Lebanon, and his MD in Medicine at the Baghdad Medical College, Baghdad, Iraq. He completed surgical residencies and his Fellowship in Clinical Hematology-Oncology at the American University of Beirut Medical Center, Beirut, Lebanon. Dr, Ibrahim completed residencies in Internal Medicine at SUNY Health Science Center, Brooklyn, NY and at St. Luke's-Roosevelt Hospital, New York, NY, and a Postdoctoral Fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center.
 
Samuel Jacobs, MD
NSABP, University of Pittsburgh Hillman Cancer Center
 Samuel Jacobs, MD is a Clinical Professor in the Department of Medicine, University of Pittsburgh School of Medicine, and the Director of Medical Affairs for the National Surgical Adjuvant Breast and Bowel Project (NSABP).  Dr. Jacobs has a long and distinguished career as a clinical researcher in the fields of breast oncology and lymphoma, with a focus on adjuvant and neo-adjuvant therapy.
 For the last four years, Dr. Jacobs has been intimately involved with the research efforts of the NSABP Foundation, Inc., which has more than 700 research sites in North America and an international network of oncology and research professionals. The NSABP pioneered breast cancer studies that led to the establishment of lumpectomy plus radiation over mastectomy as the standard surgical treatment for breast cancer and was also the first group to demonstrate that adjuvant therapy (treatment in addition to surgery) could alter the natural history of breast cancer, increase survival rates, and prevent recurrence using tamoxifen and raloxifene.
 In addition to his work in oncology treatment protocols, Dr. Jacobs has also conducted considerable research on the logistics and management of the clinical trial process, particularly in oncology. He has led the efforts at the University of Pittsburgh Clinical Research Service to provide study development and implementation assistance, IRB processing, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at all UPMC Cancer Centers.
 Dr. Jacobs received his MD from the University of Rochester, and has spent his career making the University of Pittsburgh Medical Center a leading institution in the field of oncology and cancer management.
 
Keith Knutson, PhD
Mayo Clinic
 Dr. Knutson's current interests and research focuses on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. The laboratory conducts research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes. These vaccine strategies are aimed at preventing the patients from relapsing after optimal conventional therapies. Adoptive T cell therapy is also being examined, a strategy that involves infusing high numbers of T cells into patients with active bulky malignancy.
 
In addition to his research, Dr. Knutson participates in and chairs several study sections; is Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program; Co-director, Mayo Clinic Immune Monitoring Core; and Director, Ovarian Cancer Immunotherapy Program at Mayo Clinic.
 
Dr. Knutson received his Ph.D. from the University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology: One at the University of British Columbia; and the other at the University of Washington. He was a 2004 recipient of a Howard Temin Award from the National Cancer Institute.
 
Ian Krop, MD, PhD
Dana-Farber Cancer Institute
 Ian Krop, MD is Assistant Professor, Department of Medicine, at the Dana Farber Cancer Institute at Harvard Medical School. He is a renowned leader in the field of breast cancer, with an extensive publication record focused on biomarker targeting for the improvement of clinical outcomes. Dr. Krop’s research goal is to identify novel predictive markers and therapeutic targets in breast cancer and translate these discoveries into clinically useful reagents. To accomplish this goal, he has established an ongoing collaboration with Dr Kornelia Polyak to use SAGE (Serial Analysis of Gene Expression) to identify genes important in the interaction between cancerous breast epithelial cells and tumor associated stromal cells. This technology has yielded a number of potential therapeutic targets including two chemokine receptor/ chemokine ligand pairs as well as several cathepsin family members, the expression of which is markedly dysregulated in either tumor epithelial cells and/or tumor associated stromal cells. His research laboratory is currently validating these proteins as potential targets through the use of small molecule inhibitors in in vitro and in vivo models of tumor-stromal interaction. In addition to this ongoing project, Dr. Krop is directing directing or co-directing several clinical trials with the aim of identifying novel molecular predictors of response to conventional chemotherapeutic and molecularly targeted therapies.
 Dr. Krop is Board Certified in Internal Medicine and Medical Oncology. He received his medical training and conducted his residency at Johns Hopkins University School of Medicine, and completed his Fellowship in Hematology & Oncology at Dana-Farber/Partners CancerCare.
 
Gary Lyman, MD
Duke University School of Medicine
 Gary H. Lyman MD, MPH, FASCO, FRCP(Edin) is Professor of Medicine and Director of Comparative Effectiveness and Outcomes Research – Oncology at Duke University and the Duke Cancer Institute. Dr Lyman is also a Senior Fellow at the Duke Center for Clinical Health Policy Research. Dr Lyman previously served as Professor of Medicine, Director of Medical Oncology and Chief of Medicine at the H Lee Moffitt Cancer Center and Research Institute.
 Dr. Lyman’s research interests include personalized cancer supportive care, comparative effectiveness studies of targeted therapies and biomarkers, mathematical and statistical prognostic and predictive models, advanced methods of evidence synthesis in support of clinical practice guidelines and population studies of patterns of cancer treatment and the impact of health disparities on the quality of cancer care.
 Dr Lyman is active with the American Society of Clinical Oncology, serving as Chair-Elect of the ASCO Clinical Practice Guideline Committee having chaired the Methodology Subcommittee for several years. Dr Lyman also Chairs several ASCO guideline panels including those related to Prevention and Treatment of Venous Thromboembolism in Cancer, Sentinel Node Biopsy in Early-Stage Breast Cancer and Melanoma, Use of Antiemetics in Patients Receiving Cancer Chemotherapy and Weight-Based Chemotherapy Dosing. Dr Lyman is also a member of the ASCO Biomarkers Guideline Working Group, the Comparative Effectiveness Research Task Force and the Cost of Care Task Force and in 2010, Dr Lyman received the prestigious ASCO Statesman Award and was recently elected to the ASCO Board of Directors. Dr Lyman is an advisor to the US Food and Drug Administration and the Oncology Drug Advisory Committee (ODAC). He is Editor-In-Chief of Cancer Investigation and the Peer Review Editor for ASCO’s Journal of Oncology Practice and on the Editorial Board of the Journal of Clinical Oncology and several other subspecialty journals. In addition to serving as a Fellow of ASCO, Dr Lyman is a Fellow of the Royal College of Physicians (Edinburgh), the American College of Physicians, the American College of Preventive Medicine and the American College of Clinical Pharmacology.
 Dr Lyman received his undergraduate and medical degree from the State University of New York in Buffalo and completed internal medicine residency at the University of North Carolina in Chapel Hill. He subsequently completed a Clinical Hematology/Oncology Fellowship at the Roswell Park Memorial Institute and a Postdoctoral Fellowship in Biostatistics at the Harvard School of Public Health and the Dana Farber Cancer Center.
 
Kathy D Miller, MD
Indiana University Melvin and Bren Simon Cancer Center
 Dr. Miller’s career combines both laboratory and clinical research in breast cancer. She has served as co-chair of the Hoosier Oncology Group Breast Committee since early 2002 and became co-chair of the Eastern Cooperative Oncology Group Breast Core Committee in 2010. In these roles she has worked with community oncologists to develop trials that combine clinical and biologic endpoints yet remain feasible in non-academic settings. Dr. Miller first honed her ability to coordinate multi-center trials as principal investigator for E2100, the first phase III trial to confirm the benefits of antiangiogenic therapy in patients with metastatic breast cancer. Dr. Miller currently leads E5103, an international phase III trial investigating antiangiogenic therapy in the adjuvant setting.
 Dr. Miller received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore, MD. Dr. Miller completed internal medicine training at Hopkins, then returned to her native Midwest for fellowship training at Indiana University, serving as Chief Fellow in 1997. She returned to Indiana University in 1999, attaining the rank of Associate Professor and Sheila D Ward Scholar in 2005. 
 
 James Mulé, PhD
H. Lee Moffitt Cancer Center & Research Institute
 Dr. Mulé is the Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.
 He serves on the Board of Directors of Medicine in Need, Cambridge, MA (a non-profit spin-out of Harvard University), and is a member of the Scientific and Medical Advisory Board of Aura Biosciences (a for-profit spin-out of MIT); both selected as 2010 Technology Pioneers by the World Economic Forum, Davos). Dr. Mulé remains a long-standing special government employee to the FDA and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA.
 Dr. Mulé currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A, clinical).
 Dr. Mulé has or is currently serving on the Scientific/Medical Advisory Boards of numerous privately or publicly held companies (e.g., Celgene, Genesis Biopharma), and has been or is a consultant to many others. Dr. Mulé is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. Dr. Mulé has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy. He is a 2012 nominee to the Institute of Medicine, National Academy of Sciences.
Dr. Mulé serves on the Board of Directors of Medicine in Need, Cambridge, MA (a non-profit spin-out of Harvard University), and is a member of the Scientific and Medical Advisory Board of Aura Biosciences (a for-profit spin-out of MIT); both selected as 2010 Technology Pioneers by the World Economic Forum, Davos). Dr. Mulé remains a long-standing special government employee to the FDA and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA.
 Dr. Mulé received his post-graduate degrees from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington. He then received his formal post-graduate training at the Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, and soon became a tenured, Senior Investigator there at the Surgery Branch.
 
Hope Rugo, MD
University of California, Division of Hematology and Oncology
 Dr. Rugo is a clinical professor of medicine in the division of hematology and oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she directs the Breast Oncology Clinical Trials Program. Her research interests include innovative new therapies for women with advanced breast cancer, evaluation of special circulating cells to help figure out response to therapy, complementary medicine, and supportive care.
 Dr. Rugo is an investigator in the Bay Area Spore at UCSF's Carol Franc Buck Breast Cancer Center and the principal investigator of a number of clinical trials. She has published many peer-reviewed papers and has given presentations on a variety of cancer-related topics. Dr. Rugo is a member of the Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute.
With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her M.D. from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and a fellowship in hematology and oncology at the UCSF. Additionally, she completed a two-year post-doctoral fellowship in immunology at Stanford University.

Robert E. Humphreys, MD, PhD Founder (retired)
Dr. Humphreys was the Chief Scientific Officer of Antigen Express from it's inception, and at the time of his retirement held the position of Executive Vice President. Prior to joining Antigen Express, he was Professor of Pharmacology and Medicine, and interim Chair of Pharmacology at the University of Massachusetts Medical School. He received his BS, PhD and MD at Yale, and served in the US Navy at the US Naval Hospital and Naval Medical Research Institute in Bethesda. He was a postdoctoral fellow of Dr. Jack Strominger at Harvard. He has published over 140 peer-reviewed papers and has served 10 years on NIH study sections.